Isolation of peptides from uremic plasma that inhibit phenytoin binding to normal plasma proteins
- 1 August 1981
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 30 (2) , 276-280
- https://doi.org/10.1038/clpt.1981.159
Abstract
The binding of many drugs to plasma proteins is altered in renal disease. Explanations include hypoproteinemia, alterations in the native structure of the binding protein and competitive or noncompetitive inhibition. The binding of phenytoin to proteins was studied in plasma from patients with chronic renal failure by equilibrium dialysis at 37.degree. C. Charcoal adsorption was used to normalize the binding. Substances that appeared to be peptides were isolated; they inhibited the binding of phenytoin to normal plasma proteins. The defect in phenytoin-protein binding in chronic renal failure may be due to competitive or noncompetitive inhibition by peptides.This publication has 6 references indexed in Scilit:
- Phenytoin binding to partially purified albumin in renal diseaseClinical Pharmacology & Therapeutics, 1981
- Plasma protein binding in uremia: Extraction and characterization of an inhibitorKidney International, 1980
- The effect of endogenous compounds, isolated from sera of uremic patients, on chloramphenicol binding to proteinsBiochemical Pharmacology, 1979
- Impaired plasma protein binding of phenytoin in uremia and displacement effect of salicylic acidClinical Pharmacology & Therapeutics, 1976
- CORRECTION OF PROTEIN-BINDING DEFECT IN UREMIC SERA BY CHARCOAL TREATMENT1976
- PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENTJournal of Biological Chemistry, 1951